Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AURAthis companyAura Biosciences, Inc.	$7.60	-3.1×	2.4×	0×	-2.73×	-91.0%	0.0%	0.0%	0.0%	-77.6%	-73.1%	-25.9%	0.13×	0.4×	0×	8.15×	0.0%	2	9.31	2	C+
AKTSAktis Oncology, Inc.	$16.51	-18.82×	-8.05×	181.08×	-18.73×	-80.2%	100.0%	-1149.5%	-980.9%	43.6%	-31.8%	-6.3%	-0.08×	0.43×	0×	7.37×	0.0%	2	7.26	2	C
CRBPCorbus Pharmaceuticals Holdings, Inc.	$3.61	-1.38×	0.73×	0×	-1.04×	-45.8%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-7.01	2	B-
EYPTEyePoint Pharmaceuticals, Inc.	$0.37	-5.76×	4.37×	42.66×	-5.49×	-1272.4%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.11	1	C-
IMNMImmunome, Inc.	$19.65	-8.84×	2.96×	270.32×	-5.86×	-62.2%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	23.32	2	C+
MGNXMacroGenics, Inc.	$2.38	-1.36×	1.83×	0.68×	-2.54×	-2542.6%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.42	1	D+
Peer median	—	-5.76×	1.83×	42.66×	-5.49×	-80.2%	71.1%	-776.0%	-739.4%	-53.2%	-33.5%	-18.2%	0.01×	0.34×	0×	8.07×	0.0%	2	-4.42	2	—